companies / apmoniatherapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-08 json
| total_raised | 2,624,4002.6M | ○ |
|---|---|---|
| founded | 2017 | |
| hq | Nancy, France | |
| industry | unknown | |
| stage | null |
Apmonia Therapeutics develops peptide-based immunotherapies that disrupt the tumor micro-environment and stimulate immune response in solid tumors. It serves oncologists and patients with cancers where existing checkpoint inhibitors are ineffective. The TAX2 peptide-driven approach targets thrombospondin pathways that small-molecule and antibody oncology programs have largely left untouched.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-07-15 | grant | 2,624,4002.6M | null | ○ |
| fact | status | src |
|---|---|---|
| Grant, $2.6M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |